RECRUITING

Deep Brain Stimulation Therapy in Movement Disorders

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: \- In deep brain stimulation (DBS), a device called a neurostimulator is placed in the chest. It is attached to wires in parts of the brain that affect movement. DBS might help people with movement disorders like Parkinson s disease (PD), dystonia, and essential tremor (ET). Objective: \- To provide DBS treatment to people with some movement disorders. Eligibility: \- Adults 18 years and older with PD, ET, or certain forms of dystonia. Design: * Participants will be screened with medical history and physical exam. They will have blood and urine tests and: * MRI brain scan. The participant will lie on a table that slides in and out of a metal cylinder with a magnetic field. They will be in the scanner about 60 minutes. They will get earplugs for the loud noises. During part of the MRI, a needle will guide a thin plastic tube into an arm vein and a dye will be injected. * Electrocardiogram. Metal disks or sticky pads will be placed on the chest, arms, and legs. They record heart activity. * Chest X-ray. * Tests of memory, attention, concentration, thinking, and movement. * Eligible participants will have DBS surgery. The surgery and hospital care afterward are NOT part of this protocol. * Study doctors will see participants 3 4 weeks after surgery to turn on the neurostimulator. * Participants will return every month for 3 months, then every 3 months during the first year, and every 6 months during the second year. Each time, participants will be examined and answer questions. DBS placement will be evaluated with MRI. The neurostimulator will be programmed. At two visits, participants will have tests of movements, thinking, and memory.

Official Title

Deep Brain Stimulation Therapy in Movement Disorders

Quick Facts

Study Start:2014-04-02
Study Completion:2030-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02119611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Be 18 years of age or older.
  2. * Able to comply with study procedures and provide informed consent.
  3. * Have a clinical diagnosis of idiopathic PD, primary dystonia, or ET:
  4. 1. The diagnosis of idiopathic PD will be based on the UK Brain Bank Criteria, and confirmed by the Movement Disorders Neurologists in the NIH Parkinson Clinic.
  5. 2. The diagnosis of primary (generalized or segmental), hemidystonia, or cervical dystonia will be confirmed on clinical examination in the NIH Movement Disorders Clinic.
  6. 3. The diagnosis of ET will be confirmed on clinical examination in the NIH Movement Disorders Clinic (the diagnosis of ET will be based on bilateral, largely symmetric postural or kinetic tremor involving hands and forearms that is visible and persistent. Additional or isolated tremor in head may be present but there should be the absence of abnormal posturing).
  7. * a. History of appropriate response to dopaminergic medication, with at least a 30% improvement in motor UPDRS with L-DOPA by history or in-clinic testing, for the PD patients. OR
  8. * Unsatisfactory clinical response to maximal medical management (with trials of both higher and lower doses of drugs), including:
  9. 1. good benefit from dopaminergic medication but associated with insufficient duration of action or unacceptable side-effects OR
  10. 2. intractable disabling motor fluctuations (severe off periods, dyskinesias, or freezing spells) OR
  11. 3. intractable symptoms of ET or dystonia impacting at least 2 activities of daily living.
  12. * Interested in being evaluated to undergo DBS, if indicated, to treat medically refractory movement disorder or
  13. * Patients already implanted with DBS for continued management
  1. * Clinically significant medical disease that would increase the risk of developing pre- or postoperative complications, including but not limited to uncontrolled systemic hypertension with values above 170/100; unstable heart disease; unstable respiratory disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation which cannot be interrupted;
  2. * Evidence of secondary or atypical parkinsonism/dystonia/tremor as suggested by:
  3. 1. History of stroke, exposure to toxins, neuroleptics, or encephalitis
  4. 2. Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze palsy, or multiple systems atrophy.
  5. 3. MR-imaging with evidence indicative of secondary disease such as tumor, or stroke, which could cause the movement disorder.
  6. * Dementia as evidenced by formal neuropsychological evaluation, Mattis Dementia Rating Scale (DRS-2) score, and clinical evaluations.
  7. * Unable to complete cognitive assessments and testing necessary to adequately evaluate risks and benefits of surgery.
  8. * Clinically signficiant or unstable psychiatric disorder such as severe depression or anxiety, which, in the opinion of the investigators would increase the risk of developing postoperative complications.
  9. * Unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small closed spaces (have claustrophobia), or cannot lie comfortably on their back for up to one hour.
  10. * Pregnant women.
  11. * Otherwise not eligible for DBS surgery, for example known inability to undergo anesthesia

Contacts and Locations

Study Contact

Irene H Dustin, C.R.N.P.
CONTACT
(301) 402-4479
irene.dustin@nih.gov
Debra J Ehrlich, M.D.
CONTACT
(301) 443-7888
debra.ehrlich@nih.gov

Principal Investigator

Debra J Ehrlich, M.D.
PRINCIPAL_INVESTIGATOR
National Institute of Neurological Disorders and Stroke (NINDS)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

  • Debra J Ehrlich, M.D., PRINCIPAL_INVESTIGATOR, National Institute of Neurological Disorders and Stroke (NINDS)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-04-02
Study Completion Date2030-12-01

Study Record Updates

Study Start Date2014-04-02
Study Completion Date2030-12-01

Terms related to this study

Keywords Provided by Researchers

  • Deep Brain Stimulation
  • Movement Disorders
  • Parkinson's Disease
  • Essential Tremor
  • Tourette Syndrome

Additional Relevant MeSH Terms

  • Parkinson's Disease